Research and development expenses were $10.5 million during the second quarter of 2013 compared to $8.8 million for the same period in 2012. For the six months ended June 30, 2013, research and development expenses were $20.8 million, compared to $18.2 million for the same period last year. The increase in research and development expenses is primarily due to increased external development costs related to the Company's VMAT2 program (NBI-98854) as it continues through Phase IIb clinical development.
Pipeline HighlightsElagolix UpdateAbbVie is currently conducting the initial Phase III study of elagolix for endometriosis, the Violet Petal Study. The study is a 24-week, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate to severe endometriosis-associated pain. Approximately 160 sites in the United States, Puerto Rico and Canada are conducting this study.
AbbVie is also currently conducting a Phase IIb study of elagolix in uterine fibroids. This study is assessing uterine blood loss in 280 women with heavy uterine bleeding due to uterine fibroids.
The manuscript for the elagolix Daisy Petal Study (901 study) entitled "Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study" has been accepted for future print publication in the Journal of Endometriosis and Pelvic Pain Disorders. The electronic version of the manuscript is currently available from this quarterly peer reviewed journal.
VMAT2 UpdateThe Company is currently conducting two Phase IIb studies of its VMAT2 inhibitor, NBI-98854.
The Kinect Study completed enrollment
|SOURCE Neurocrine Biosciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved